Drug utilization pattern and selected biochemical parameters in pre- and post-hemodialysis state in the end stage renal disease patients: a cross sectional study at a tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20194119Keywords:
ESRD, Haemodialysis, Poly-pharmacy, Drug utilization patternAbstract
Background: Chronic kidney disease can progress to end-stage kidney failure (ESRD), which is fatal without artificial filtering (dialysis) or a kidney transplant.
Methods: The ESRD patients of either gender age >18 years who were diagnosed by nephrologist as ESRD and are on haemodialysis regularly included for the study.
Results: The blood urea, serum creatinine, phosphorous, potassium levels were reduced significantly in post – haemodialysis condition, but, there was not much weight reduction after haemodialysis. Serum albumin, serum sodium and blood haemoglobin levels were almost unchanged in post – haemodialysis state. There was no significant difference between the pre and post haemodialysis parameters- serum Na+ serum albumin and blood hemoglobulin. Out of 75 ESRD patients, almost all patients 74 (98.7%) prescribed tablet Livogen, 73 (97.3%) patients given Inj. EPO, 55 (73.3%) tab Nicardia, 54 (76%) tab Sodamint, 43 (57.3%) capsule Alpha D3, 40 (53.3%) tab Shelcal. While between 12 (16%) to 20 (26%) patients prescribed tab Nodosis, tab Metoprolol, tab Febuget, tab Ecosprin, and tab Rantac. Only 1 (1.3%) to 9 (12%) patients received tablet Augmentin, tab Arkamine, tab Carvedilol, tab Para 500, tab Atorvas, Human mixtard, tab Calcicard, tab Minipress XL, tab Dytor, and tab Clopilet.
Conclusions: The available two models of treatment, i.e., haemodialysis and poly pharmacy at hospital setup to face the challenges associated with the ESRD, and even outcome after application of both these two models of therapies did not provide optimal normal healthy life status to ESRD patients.
References
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US Population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
Singh AK, Farag YMK, Mittal BV, Subramanian KK, Reddy SRK, Acharya VN, et al. Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney disease) study. BMC Nephrol. 2013;14:114.
Chawla S, Ranjan A, Singh NP, Garg N, Kumar A. Assessment of drug utilization and quality of life in Patients of chronic kidney disease in a tertiary care Hospital. World J Pharmacy Pharm Sci. 2016;5(9):1214-26.
Shah J, Khakhkhar T, Bhirud S, Shah RB, Date S. Study of utilization pattern of anti-hypertensive drugs in hypertensive diabetic patients with or without reduced renal function at tertiary care teaching hospital. Int J Med Sci Public Health. 2013;2:175-80.
Sarhat E, Murtadha NA. Biochemical Changes in Chronic Renal Failure Pre and Post Hemodialysis. J Environ Sci Engineering. 2016;5:190-5.
Safar Michel E. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39(3):735-8.
El-Kishawi, El-Nahas. Renal Osteodystrophy: Review of the Disease and its Treatment. Saudi J Kid Dis Transplant. 2006;17(3):373-82.
Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166:1884–91.
Tamilselvan T, Veerapandiyan AK, Karthik N. Study on drug utilization pattern of chronic renal failure patients in a tertiary care hospital. Int J Pharm Pharm Sci. 204;6(9):482-4.
Amin N, Mahmood RT, Asad MJ, Zafar M, Raja AM. Evaluating Urea and Creatinine Levels in Chronic Renal Failure Pre and Post Dialysis: A Prospective Study. J Cardiovascular Dis. 2014;2(2):1-4.
